These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36425562)

  • 1. Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making.
    Sun D; Xu M; Pan C; Tang H; Wang P; Wu D; Luo H
    Front Oncol; 2022; 12():972972. PubMed ID: 36425562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor mutational burden assessment and standardized bioinformatics approach using custom NGS panels in clinical routine.
    Dupain C; Gutman T; Girard E; Kamoun C; Marret G; Castel-Ajgal Z; Sablin MP; Neuzillet C; Borcoman E; Hescot S; Callens C; Trabelsi-Grati O; Melaabi S; Vibert R; Antonio S; Franck C; Galut M; Guillou I; Halladjian M; Allory Y; Cyrta J; Romejon J; Frouin E; Stoppa-Lyonnet D; Wong J; Le Tourneau C; Bièche I; Servant N; Kamal M; Masliah-Planchon J
    BMC Biol; 2024 Feb; 22(1):43. PubMed ID: 38378561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
    Merino DM; McShane LM; Fabrizio D; Funari V; Chen SJ; White JR; Wenz P; Baden J; Barrett JC; Chaudhary R; Chen L; Chen WS; Cheng JH; Cyanam D; Dickey JS; Gupta V; Hellmann M; Helman E; Li Y; Maas J; Papin A; Patidar R; Quinn KJ; Rizvi N; Tae H; Ward C; Xie M; Zehir A; Zhao C; Dietel M; Stenzinger A; Stewart M; Allen J;
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?
    Noskova H; Kyr M; Pal K; Merta T; Mudry P; Polaskova K; Ivkovic TC; Adamcova S; Hornakova T; Jezova M; Kren L; Sterba J; Slaby O
    Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31963488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interplay between Tumor Mutational Burden and Mutational Profile and Its Effect on Overall Survival: A Pilot Study of Metastatic Patients Treated with Immune Checkpoint Inhibitors.
    Xavier CB; Lopes CDH; Awni BM; Campos EF; Alves JPB; Camargo AA; Guardia GDA; Galante PAF; Jardim DL
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
    Zheng M
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tumor mutation burden calculation from gene panel sequencing data.
    Xu Z; Dai J; Wang D; Lu H; Dai H; Ye H; Gu J; Chen S; Huang B
    Onco Targets Ther; 2019; 12():3401-3409. PubMed ID: 31123404
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
    Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
    BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers.
    Mo SF; Cai ZZ; Kuai WH; Li X; Chen YT
    Front Cell Dev Biol; 2023; 11():1209243. PubMed ID: 37305681
    [No Abstract]   [Full Text] [Related]  

  • 13. Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer.
    Park S; Lee C; Ku BM; Kim M; Park WY; Kim NKD; Ahn MJ
    BMB Rep; 2021 Jul; 54(7):386-391. PubMed ID: 34154699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
    Choi SJ; Lee JB; Kim JH; Hong MH; Cho BC; Lim SM
    Ther Adv Med Oncol; 2024; 16():17588359241240657. PubMed ID: 38523846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
    Hatakeyama K; Nagashima T; Urakami K; Ohshima K; Serizawa M; Ohnami S; Shimoda Y; Ohnami S; Maruyama K; Naruoka A; Akiyama Y; Kusuhara M; Mochizuki T; Yamaguchi K
    Biomed Res; 2018; 39(3):159-167. PubMed ID: 29899191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden.
    Necchi A; Spiess PE; Costa de Padua T; Li R; Grivas P; Huang RSP; Lin DI; Danziger N; Ross JS; Jacob JM; Sager RA; Basnet A; Li G; Graf RP; Pavlick DC; Bratslavsky G
    JAMA Netw Open; 2023 Dec; 6(12):e2348002. PubMed ID: 38150257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
    Hong TH; Cha H; Shim JH; Lee B; Chung J; Lee C; Kim NKD; Choi YL; Hwang S; Lee Y; Park S; Jung HA; Kim JY; Park YH; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH; Park WY
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33077514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.
    Klempner SJ; Fabrizio D; Bane S; Reinhart M; Peoples T; Ali SM; Sokol ES; Frampton G; Schrock AB; Anhorn R; Reddy P
    Oncologist; 2020 Jan; 25(1):e147-e159. PubMed ID: 31578273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing.
    Zhou C; Chen S; Xu F; Wei J; Zhou X; Wu Z; Zhao L; Liu J; Guo W
    Ann Transl Med; 2021 Sep; 9(18):1437. PubMed ID: 34733989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.